CO6382184A2 - Proteinas fijadoras de receptores de interleukinas-21 - Google Patents

Proteinas fijadoras de receptores de interleukinas-21

Info

Publication number
CO6382184A2
CO6382184A2 CO10160884A CO10160884A CO6382184A2 CO 6382184 A2 CO6382184 A2 CO 6382184A2 CO 10160884 A CO10160884 A CO 10160884A CO 10160884 A CO10160884 A CO 10160884A CO 6382184 A2 CO6382184 A2 CO 6382184A2
Authority
CO
Colombia
Prior art keywords
fixing
antigen
fragment
protein
interleukinas
Prior art date
Application number
CO10160884A
Other languages
English (en)
Inventor
Laird Bloom
Davinder Gill
Viia Valge Archer
David Lowe
Deborah Ann Young
Yulia Vugmeyster
Original Assignee
Wyeth Llc
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6382184(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc, Medimmune Ltd filed Critical Wyeth Llc
Publication of CO6382184A2 publication Critical patent/CO6382184A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

1.- Una proteína fijadora aislada o fragmento fijador de antígenos de la misma que se fija a IL-21 R, en donde la proteína fijadora o fragmento fijador de antígenos de la misma comprende al menos una secuencia aminoácida que es al menos aproximadamente 95% idéntica a una secuencia aminoácida seleccionada del grupo que consta de SEQ LD NOs: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42,44,46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120,122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 165-168, 171-193, 213-229, 240, 242, 244, 246, y 248.2.- La proteína fijadora aislada o fragmento fijador de antígenos de la reivindicación 1, en donde la proteína fijadora o fragmento fijador de antígenos es un anticuerpo.3.- La proteína fijadora aislada o fragmento fijador de antígenos de la reivindicación 1, en donde la proteína fijadora o fragmento fijador de antígenos es un scFv.
CO10160884A 2008-05-23 2010-12-22 Proteinas fijadoras de receptores de interleukinas-21 CO6382184A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23

Publications (1)

Publication Number Publication Date
CO6382184A2 true CO6382184A2 (es) 2012-02-15

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10160884A CO6382184A2 (es) 2008-05-23 2010-12-22 Proteinas fijadoras de receptores de interleukinas-21

Country Status (20)

Country Link
US (2) US8163884B2 (es)
EP (1) EP2297199A1 (es)
JP (1) JP2011523849A (es)
KR (1) KR20110040773A (es)
CN (1) CN102105491A (es)
AR (1) AR071885A1 (es)
AU (1) AU2009248809A1 (es)
CA (1) CA2724915A1 (es)
CL (1) CL2009001284A1 (es)
CO (1) CO6382184A2 (es)
IL (1) IL209328A0 (es)
MX (1) MX2010012811A (es)
MY (1) MY149448A (es)
NZ (1) NZ589330A (es)
PE (1) PE20100141A1 (es)
RU (1) RU2010152690A (es)
SA (1) SA109300315B1 (es)
TW (1) TW201000129A (es)
WO (1) WO2009143523A1 (es)
ZA (1) ZA201008335B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US20130004976A1 (en) * 2009-12-25 2013-01-03 Sekisui Medical Co., Ltd. Human insulin assay and assay reagent
ES2628841T3 (es) * 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
BR0008772B1 (pt) 1999-03-09 2011-11-01 vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU5142300A (en) 1999-05-18 2000-12-05 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
US6777539B2 (en) 2000-04-05 2004-08-17 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
DE60124954T2 (de) 2000-05-11 2007-09-20 Genetics Institute, LLC, Cambridge Mu-1, ein mitglied der cytokine rezeptor familie
ATE444363T1 (de) 2001-11-05 2009-10-15 Zymogenetics Inc Il-21-antagonisten
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
ES2381265T3 (es) 2002-06-07 2012-05-24 Zymogenetics, Inc. Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos
CN1688340A (zh) 2002-07-15 2005-10-26 韦思公司 调节t辅助(th)细胞发育和功能的方法和组合物
ES2340280T3 (es) * 2003-03-14 2010-06-01 Wyeth Llc Anticuerpos dirigidos contra el receptor de il-21 humano y uso de los mismos.
WO2004084835A2 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
JP2007506789A (ja) 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
EP1753458A4 (en) 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
AR051071A1 (es) 2004-08-05 2006-12-20 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina-21
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
AU2009248809A1 (en) 2009-11-26
RU2010152690A (ru) 2012-06-27
US20090298167A1 (en) 2009-12-03
KR20110040773A (ko) 2011-04-20
PE20100141A1 (es) 2010-02-22
CN102105491A (zh) 2011-06-22
CL2009001284A1 (es) 2009-11-27
IL209328A0 (en) 2011-01-31
MX2010012811A (es) 2011-05-19
ZA201008335B (en) 2014-04-30
CA2724915A1 (en) 2009-11-26
EP2297199A1 (en) 2011-03-23
MY149448A (en) 2013-08-30
US8163884B2 (en) 2012-04-24
US20120264919A1 (en) 2012-10-18
TW201000129A (en) 2010-01-01
SA109300315B1 (ar) 2012-08-28
NZ589330A (en) 2012-12-21
JP2011523849A (ja) 2011-08-25
WO2009143523A1 (en) 2009-11-26
AR071885A1 (es) 2010-07-21

Similar Documents

Publication Publication Date Title
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CU20120095A7 (es) Antagonistas de pcsk9
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
RU2018132044A (ru) Антитела против тау
PE20150222A1 (es) Anticuerpos multiespecificos
CY1116525T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
NZ598770A (en) Monoclonal antibodies
UA111818C2 (uk) Антитіло проти csf-1r
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
CO5720212A1 (es) Composicion de anticuerpo her2
EA201790757A1 (ru) Связывающие антиген cd27l белки
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
EA201100868A1 (ru) Противоопухолевые комбинации, содержащие антитела, специфически распознающие cd38, и цитарабин

Legal Events

Date Code Title Description
FC Application refused